Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 14/20 | 1.00 |
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | CA2 | P00918 | 4/20 | 0.50 |
| ▸ | CA4 | P22748 | 4/20 | 0.50 |
| ▸ | CA6 | P23280 | 4/20 | 0.50 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.47 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4078284 | 0.91 | PARP1 (1.00) | PARP1CA1CA2CA4CA6 | |
| SCHEMBL8272677 | 0.84 | PARP1 (0.72) | PARP1CA1CA2CA4CA6 | |
| SCHEMBL14079320 | 0.84 | PARP1 (0.72) | PARP1CA1CA2CA4CA6 | |
| SCHEMBL2763222 | 0.83 | PARP1 (0.70) | PARP1CA1CA2CA4CA6 | |
| SCHEMBL14169785 | 0.81 | PARP1 (0.67) | PARP1CA1CA2CA4CA6 | |
| SCHEMBL4661629 | 0.80 | PARP1 (1.00) | PARP1CA1CA2CA4CA6 | |
| SCHEMBL13376139 | 0.78 | PARP1 (0.72) | PARP1CA1CA2CA4CA6 | |
| SCHEMBL14079321 | 0.78 | PARP1 (0.72) | PARP1CA1CA2CA4CA6 | |
| SCHEMBL13377548 | 0.77 | PARP1 (0.77) | PARP1CA1CA2CA4CA6 | |
| SCHEMBL29496073 | 0.77 | PARP1 (0.77) | PARP1CA1CA2CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1868607-A4 | ISOQUNOLINE COMPOUNDS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORP (US) | 2008-05-14 | — | — | EP | disclosed |
| EP-1868607-A2 | ISOQUNOLINE COMPOUNDS AND METHODS OF USE THEREOF | Inotek Pharmaceuticals Corporation (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20060287313-A1 | Isoquinoline compounds and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2006-12-21 | — | — | US | disclosed |
| WO-2006093666-A2 | ISOQUNOLINE COMPOUNDS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287313-A1 | Isoquinoline compounds and methods of use thereof | GLS, PINK1, PARK7 | PARP1 256/4885CA1 3617/4885CA2 3958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.